Table 3. Main results of the meta-analysis for the association of HIF1A gene 1772 C/T and 1790 G/A polymorphisms with cancer risk.
| 1772 C/T polymorphisms (rs11549465) |
TT VS CC |
CT VS CC |
TT/CT VS CC |
TT VS CT/CC
|
T allele VS C allele |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | Sample size | ORa | P b | ORa | P b | ORa | P b | ORa | P b | ORa | P b | |
| Total | 34 | 7522 | 2.45 (1.52–3.96) | 0.028 | 1.15 (0.92–1.45) | <0.001 | 1.27 (1.05–1.55) | <0.001 | 3.18 (1.92–5.29) | <0.001 | 1.42 (1.18–1.70) | <0.001 |
| Total in HWE | 25 | 6575 | 3.65 (2.47–5.40) | 0.318 | 1.29 (1.04–1.62) | <0.001 | 1.35 (1.10–1.65) | <0.001 | 3.38 (2.29–5.00) | 0.476 | 1.40 (1.15–1.71) | <0.001 |
| Cancer types | ||||||||||||
| Breast cancer | 5 | 2047 | 2.30 (1.08–4.91) | 0.084 | 1.07 (0.88–1.29) | 0.188 | 1.12 (0.92–1.35) | 0.711 | 2.27 (1.06–4.87) | 0.120 | 1.09 (0.76–1.55) | 0.022 |
| Lung cancer | 3 | 509 | 1.41 (0.07–30.4) | 0.044 | 1.13 (0.59–2.19) | 0.018 | 1.50 (1.15–1.96) | 0.688 | 3.27 (1.73–6.17) | 0.065 | 1.19 (0.50–2.86) | <0.001 |
| Oral cancer | 3 | 284 | 2.01 (0.75–5.41) | 0.463 | 0.85 (0.24–2.97) | 0.047 | 1.04 (0.61–1.78) | 0.823 | 22.8 (0.28–1888) | <0.001 | 3.93 (0.61–25.4) | <0.001 |
| Colorectal cancer | 4 | 627 | 1.91 (0.32–11.6) | 0.24 (0.01–5.51) | 0.027 | 1.10 (0.87–1.38) | 0.744 | 1.97 (0.33–11.9) | 1.36 (0.68–2.70) | 0.002 | ||
| Prostate cancer | 5 | 2396 | 3.68 (1.58–8.55) | 0.871 | 2.02 (1.01–4.07) | <0.001 | 2.10 (1.08–4.09) | 0.028 | 3.52 (1.52–8.16) | 0.847 | 2.06 (1.15–3.68) | <0.001 |
| Cervical cancer | 3 | 328 | 10.1 (3.12–32.6) | 0.153 | 1.37 (0.92–2.02) | 0.099 | 1.63 (1.12–2.37) | 0.158 | 8.26 (2.64–25.9) | 0.236 | 1.89 (0.84–4.26) | 0.002 |
| Others | 13 | 1331 | 1.68 (0.42–6.80) | <0.001 | 0.97 (0.56–1.68) | <0.001 | 1.20 (0.98–1.47) | 0.512 | 1.99 (1.40–2.84) | 0.100 | 1.37 (0.96–1.97) | <0.001 |
| Ethnicities | ||||||||||||
| Caucasian | 15 | 2151 | 1.70 (0.81–3.55) | 0.001 | 0.86 (0.57–1.31) | <0.001 | 1.05 (0.76–1.46) | <0.001 | 2.97 (1.44–6.14) | <0.001 | 1.32 (0.99–1.75) | <0.001 |
| Asian | 17 | 4134 | 4.42 (2.07–9.43) | 0.997 | 1.25 (0.98–1.60) | 0.010 | 1.33 (1.06–1.68) | 0.006 | 4.12 (1.93–8.77) | 0.955 | 1.40 (1.11–1.78) | 0.002 |
| Mixed | 2 | 1237 | 3.13 (0.90–10.8) | 0.500 | 2.98 (1.92–4.63) | 0.372 | 3.05 (2.00–4.66) | 0.269 | 2.77 (0.80–9.54) | 0.646 | 2.91 (1.96–4.32) | 0.208 |
| Source of control | ||||||||||||
| PB | 21 | 4944 | 1.92 (1.05–3.50) | 0.037 | 0.99 (0.69–1.41) | <0.001 | 1.17 (0.87–1.57) | <0.001 | 3.14 (1.60–6.16) | <0.001 | 1.40 (1.06–1.84) | <0.001 |
| HB | 13 | 2578 | 4.38 (2.64–7.47) | 0.486 | 1.32 (1.13–1.57) | 0.023 | 1.39 (1.09–1.77) | 0.002 | 3.88 (2.32–6.51) | 0.569 | 1.46 (1.16–1.85) | <0.001 |
| 1790 G/A polymorphisms (rs11549465) | AA VS GG | GA VS GG | AA/GA VS GG | AA VS GA/GG | A allele VS G allele | |||||||
| N | Sample size | ORa | P b | ORa | P b | ORa | P b | ORa | P b | ORa | P b | |
| Total | 24 | 5136 | 4.74 (1.78–12.6) | 0.002 | 1.35 (0.82–2.21) | <0.001 | 1.65 (1.05–2.60) | <0.001 | 4.39 (1.61–11.9) | 0.001 | 1.83 (1.13–2.96) | <0.001 |
| Total in HWE | 23 | 5090 | 4.68 (1.34–16.3) | 0.001 | 1.23 (0.77–1.98) | <0.001 | 1.53 (0.99–2.36) | <0.001 | 4.65 (1.35–16.0) | 0.001 | 1.83 (1.13–2.96) | <0.001 |
| Cancer types | ||||||||||||
| Breast cancer | 3 | 521 | 1.44 (0.38–5.44) | 0.336 | 1.03 (0.70–1.52) | 0.115 | 1.05 (0.72–1.53) | 0.077 | 1.41 (0.37-5.37) | 0.356 | 1.07 (0.75-1.52) | 0.055 |
| Lung cancer | 3 | 362 | 5.42 (2.75–10.7) | 0.866 | 0.26 (0.01–7.10) | <0.001 | 0.82 (0.56–1.19) | 0.226 | 7.11 (3.61–14.0) | 0.975 | 1.48 (1.09-2.00) | 0.575 |
| Oral cancer | 3 | 375 | 20.7(0.10–4519) | <0.001 | 2.21 (0.18–26.9) | <0.001 | 7.81 (0.27–224) | <0.001 | 17.5 (0.10–3257) | <0.001 | 9.34 (0.23-388) | <0.001 |
| Prostate cancer | 3 | 1865 | 3.35 (0.14–82.3) | 1.41 (0.97–2.07) | 0.365 | 1.44 (0.98–2.10) | 0.340 | 3.25 (0.13–79.9) | 1.45 (1.00-2.11) | 0.330 | ||
| Others | 14 | 1542 | 4.81 (2.34–9.87) | 0.460 | 1.70 (0.99–2.90) | <0.001 | 1.80 (0.99–3.26) | <0.001 | 3.01 (1.47–6.21) | 0.367 | 1.91 (1.01-3.58) | <0.001 |
| Ethnicities | ||||||||||||
| Caucasian | 12 | 1635 | 17.4 (4.01-75.3) | 0.001 | 1.09 (0.33–3.58) | <0.001 | 2.19 (0.90–5.34) | <0.001 | 15.8(3.42–72.9) | <0.001 | 2.27 (0.92-5.58) | <0.001 |
| Asian | 11 | 2435 | 1.44 (0.60-3.46) | 0.522 | 1.45 (0.85–2.46) | <0.001 | 1.36 (0.83–2.24) | <0.001 | 1.41 (0.58–3.39) | 0.508 | 1.42 (0.84-2.40) | <0.001 |
| Source of control | ||||||||||||
| PB | 14 | 3013 | 9.69 (1.41-66.7) | <0.001 | 1.40 (0.71–2.74) | <0.001 | 1.80 (0.89–3.64) | <0.001 | 8.08 (1.12–58.1) | <0.001 | 2.10 (0.95-4.68) | <0.001 |
| HB | 10 | 2123 | 4.08 (2.26-7.37) | 0.401 | 1.23 (0.53–2.86) | <0.001 | 1.47 (0.85–2.55) | <0.001 | 5.02 (2.79–9.02) | 0.278 | 1.50 (0.86-2.62) | <0.001 |
a Random-effects model was used when the P value for the heterogeneity test was < 0.05; otherwise, fixed-effects model was used.
b P Value of Q-Test for the Heterogeneity Test
N: number of studies included; OR: odds ratio; PB: population-based; HB: hospital-based; HWE= Hardy–Weinberg equilibrium.
One study contained detailed data on ovarian cancer, endometrial cancer, and cervical cancer. We used the combined data for the overall analysis and the separate data for the subgroup analysis by cancer type.